Postlumpectomy Focal Brachytherapy for Simultaneous Treatment of Surgical Cavity and Draining Lymph Nodes

The primary objective was to investigate a novel focal brachytherapy technique using lipid nanoparticle (liposome)–carried β-emitting radionuclides (rhenium-186 [ 186Re]/rhenium-188 [ 188Re]) to simultaneously treat the postlumpectomy surgical cavity and draining lymph nodes. Cumulative activity dis...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of radiation oncology, biology, physics Vol. 79; no. 3; pp. 948 - 955
Main Authors Hrycushko, Brian A., Li, Shihong, Shi, Chengyu, Goins, Beth, Liu, Yaxi, Phillips, William T., Otto, Pamela M., Bao, Ande
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.03.2011
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The primary objective was to investigate a novel focal brachytherapy technique using lipid nanoparticle (liposome)–carried β-emitting radionuclides (rhenium-186 [ 186Re]/rhenium-188 [ 188Re]) to simultaneously treat the postlumpectomy surgical cavity and draining lymph nodes. Cumulative activity distributions in the lumpectomy cavity and lymph nodes were extrapolated from small animal imaging and human lymphoscintigraphy data. Absorbed dose calculations were performed for lumpectomy cavities with spherical and ellipsoidal shapes and lymph nodes within human subjects by use of the dose point kernel convolution method. Dose calculations showed that therapeutic dose levels within the lumpectomy cavity wall can cover 2- and 5-mm depths for 186Re and 188Re liposomes, respectively. The absorbed doses at 1 cm sharply decreased to only 1.3% to 3.7% of the doses at 2 mm for 186Re liposomes and 5 mm for 188Re liposomes. Concurrently, the draining sentinel lymph nodes would receive a high focal therapeutic absorbed dose, whereas the average dose to 1 cm of surrounding tissue received less than 1% of that within the nodes. Focal brachytherapy by use of 186Re/ 188Re liposomes was theoretically shown to be capable of simultaneously treating the lumpectomy cavity wall and draining sentinel lymph nodes with high absorbed doses while significantly lowering dose to surrounding healthy tissue. In turn, this allows for dose escalation to regions of higher probability of containing residual tumor cells after lumpectomy while reducing normal tissue complications.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0360-3016
1879-355X
1879-355X
DOI:10.1016/j.ijrobp.2010.05.062